Increasing the effectiveness of psychodynamic short-term psychotherapy for anxiety disorders by adding elements of Emotion Focused Therapy: An open proof of concept trial

Increasing the effectiveness of psychodynamic short-term psychotherapy for anxiety disorders by adding elements of Emotion Focused Therapy: An open proof of concept trial - EFPP

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00013478

Enrollment

Registered

2017-12-05

Start date

2018-02-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety disorders: Social Phobia, Generalized anxiety disorder, Panic disorder/ Agoraphobia F40.1 F41.1 F41.0 F40.01

Interventions

Group 1: Psychodynamic short term psychotherapy (STPP) integrating elements of emotion focused therapy (EFT)

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Diagnosis of an Anxiety disorder (SP, Panic/Agoraphobia, GAD, SCID-I) Anxiety disorder must be primary diagnosis (most severe disorder according to ADIS-IV) Patients with anxiety disorders with comorbid disorders will be included, provided that the anxiety disorder is the primary diagnosis, thus ensuring a clinically representative sample age: 18 to 70 years Informed consent

Exclusion criteria

Exclusion criteria: psychotic disorder prominent risk of self-harm acute substance related disorders personality disorders except for avoidant and dependent personality disorder (SCID-II) Posttraumatic Stress Disorder (PTSD) and/or sexual abuse in childhood organic mental disorder severe medical conditions concurrent psychotherapeutic treatment psychopharmacological treatment (stable medical treatments (e.g. SSRI without dose adaptation are permitted)

Design outcomes

Primary

Measure	Time frame
Clinical Global Impression (CGI-scale) after treatment	—

Secondary

Measure	Time frame
Secondary endpoints: Anxiety (Mobility index, MI, Body Sensations Questionnaire, BSQ, Agoraphobic Cognitions Questionnaire, ASQ, Liebowitz Social Anxiety Scale, LSAS, Penn State Worry Questionnaire, PSWQ), depression (PHQ-9), quality of life and social functioning (EQ-5D), distress (global severity index, SCL-90), Emotion regulation skills (SEK-27), resilience (RS-11), Working alliance (WAI-12R). Therapists and patients will be asked for the feasibility and acceptance of the treatment (ZUF-8) Safety: Description of serious adverse events and drop-outs Assessments at baseline, after 8 sessions, after 16 sessions, and after 25 sessions (post-treatment), 3 months after end of treatment.	—

Measure

Time frame

Secondary endpoints: Anxiety (Mobility index, MI, Body Sensations Questionnaire, BSQ, Agoraphobic Cognitions Questionnaire, ASQ, Liebowitz Social Anxiety Scale, LSAS, Penn State Worry Questionnaire, PSWQ), depression (PHQ-9), quality of life and social functioning (EQ-5D), distress (global severity index, SCL-90), Emotion regulation skills (SEK-27), resilience (RS-11), Working alliance (WAI-12R). Therapists and patients will be asked for the feasibility and acceptance of the treatment (ZUF-8) Safety: Description of serious adverse events and drop-outs Assessments at baseline, after 8 sessions, after 16 sessions, and after 25 sessions (post-treatment), 3 months after end of treatment.

—

Countries

Germany

Contacts

Public ContactClaudia Subic-Wrana

Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie, Universitätsmedizin der Johannes Gutenberg-Universität Mainz

Claudia.Subic-Wrana@unimedizin-mainz.de06131 8928781

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026